Scarica l'app Stockscreener
3.39
0.29%
-0.010
Dopo l'orario di chiusura:
3.39
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus
ADC reports data from lymphoma trial, streamlines operations - MSN
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
TradingKey - TradingKey
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - Quantisnow
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation - MSN
ADC Therapeutics (ADCT) Earnings Date and Reports 2026 - MarketBeat
Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst - MarketBeat
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report - simplywall.st
ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha
ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey
ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart
ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call - Benzinga
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics Reports Narrower Q1 2026 Loss, Beats Estimates - AlphaStreet
ADC Therapeutics Q1 2026: $0.13/share Loss Beats Estimates — Deep Dive - AlphaStreet
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M - Stock Titan
ADC Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ADC Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Reports Q1 2026 Financial Results and Updates – NYSE: ADCT - Minichart
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ADC Therapeutics Q1 Earnings Call Highlights - MarketBeat
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
ADC Therapeutics : (ADCT 1Q 2026 Earnings) - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued - ChartMill
The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company's cash and cash equivalents totaled 231 million USD. - Bitget
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q1 2026 Earnings - Quiver Quantitative
ADC Therapeutics reports Q1 2026: $20.0M net product revenue, $32.97M net loss - TradingView
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028 - Stock Titan
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - marketscreener.com
Earnings Scheduled For May 4, 2026 - Benzinga
MSN Money - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GuruFocus
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Singapore
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan – Company Announcement - Financial Times
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
ADC Therapeutics schedules May 4 webcast on Q1 results and operations - Stock Titan
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):